Psychedelic compounds—traditionally including LSD, ketamine, and psilocybin—are being chemically modified to remove hallucinogenic properties, creating therapeutic opportunities for conditions like major depressive disorder and post-traumatic stress disorder. Legal and regulatory frameworks must evolve to support this emerging industry while acknowledging the historical pioneers who developed foundational knowledge.
Standardizing Clinical Trial Protocols
Nature Medicine recently published guidelines called Reporting of Setting in Psychedelic Clinical Trails (ReSPCT) that establish standardized protocols for psychedelic clinical trials. The framework includes thirty variables covering the administration environment, dosing procedures, practitioner intake methods, and patient therapeutic experiences. However, current clinical trials for psychedelics do not yet provide the necessary framework for the FDA to rely on the clinical endpoints these protocols establish. These guidelines recognize industry fears about potential patient harm while accounting for the high therapeutic ceiling these compounds may offer.
Protecting Prior Knowledge and Traditional Practices
A critical gap exists in recognizing the centuries of Indigenous practice underlying modern psychedelic research. Porta Sophia, a nonprofit organization, has created a database of prior art references to help researchers, patent examiners, and Indigenous practitioners navigate patent applications. This database protects Indigenous knowledge from external claims while providing inventors with access to existing knowledge and potential patients with access to public domain alternatives.
The source text proposes a “ceremonial use” defense to patent infringement that would protect users from infringement claims related to religious practices. This defense would resemble existing prior user rights doctrine, where patent owners cannot sue for continued private use of a technology predating patent issuance.
Industry Cooperation and Political Support
As the market matures, companies could adopt patent pledges similar to those used during the COVID-19 pandemic, voluntarily limiting patent enforcement to spur affordable access and follow-on innovation. Although empirical evidence on patent pledge effectiveness remains limited, data suggests pledged patents can stimulate startup activity.
Political momentum is building across the spectrum. HHS Secretary R.F.K. Jr. announced plans in June 2025 to deploy new psychedelic drugs to clinical settings within twelve months, while Texas Governor Greg Abbot signed legislation investing $50 million into psychedelic clinical trials. Representatives Alexandria Ocasio-Cortez (D-NY) and Dan Crenshaw (R-Texas) both supported the House National Defense Authorization Act’s allowance of psychedelic medical research.
The source text argues that establishing clear regulatory legislation now—before the industry fully matures—can ensure therapies derived from psychedelic compounds are both safe and effective while fairly rewarding pioneers who developed this field.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.womblebonddickinson.com/us/insights/alerts/actualizing-therapy-psychedelic-compounds-requires-acknowledging-past-pioneers-well